Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling

Blood

Volumn 97, Issue 6, 2001, Pages 1823-1834

  Morgan, Michael A ^a   Dolp, Oliver ^a   Reuter, Christoph W M ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; ONCOPROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035869396     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.6.1823     Document Type: Article

References (88)

1. RAS oncogenes in human cancer: A review
2. Ras proto-oncogene activation in human malignancy
3. The Ras branch of small GTPases: Ras family members don't fail far from the tree
4. Ras proteins: Recent advances and new functions
5. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematological malignancies
6. Protein prenylation: Molecular mechanisms and functional consequences
7. Protein prenylation, et cetera: Signal transduction in two dimensions
8. Reversible palmitoylation of signaling proteins
9. Signal transduction via Ras
10. Ras effectors
11. Signal transduction from multiple Ras effectors
12. Evidence for a Ras/Ral signaling cascade
13. Phosphoinositide kinases
14. The ins and outs of Raf kinases
15. Raf gets it together
16. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
17. Signaling networks - Do all roads lead to the same genes
18. Mitogen-activated protein kinase pathways
19. Organization and regulation of mitogen-activated protein kinase signaling pathways
20. Regulation of transcription by MAP kinase cascades
21. Chronic myelomonocytic leukemia: Tel-a-kinase what ets all about
22. The molecular pathophysiology of myeloid leukaemias: Ras revisited
23. RAS and leukemia: From basic mechanisms to gene-directed therapy
24. Mutations of K-Ras oncogene in human adrenal tumors in Taiwan
25. Decreased GTPase activity of K-Ras deriving from human functional adrenocortical tumours
26. G protein mechanisms: Insights from structural analysis
27. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia
28. Constitutively activating mutations of c-Kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines
29. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders
30. Prognostic implication of FLT3 and N-Ras gene mutations in acute myeloid leukemia
31. Mitogenic signaling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells
32. Fusion of PDGF receptor (to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
33. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRβ oncoprotein
34. The novel activation of abl by fusion to an ets-related gene, tel
35. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
36. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase
37. The leukaemic oncoproteins BCR-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signaling pathways
38. Abnormal regulation of mammalian p21 ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
39. Genetic analysis is consistent with the hypothesis that NF-1 limits myeloid cell growth through p21ras
40. Loss of NF-1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells
41. NF-1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia
42. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents
43. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
44. Therapeutic intervention and signaling
45. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
46. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
47. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony stimulating factor
48. Immune complex kinase assays for mitogen-activated protein kinase and MEK
49. Biochemical analysis of MEK activation in NIH3T3 fibroblasts
50. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding
51. Cell cycle-dependent activation of Ras
52. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras
53. Ras mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia
54. N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/paroxysmal nocturnal hemoglobinuria during evolution to clonal disease
55. Detection of allele-specific expression of N-Ras oncogenes in human leukaemia cells
56. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice
57. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells
58. Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation
59. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: Combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1
60. Nuclear localization and regulation of ERK- and RSK-encoded protein kinases
61. Serum-induced translocation of mitogen-activated protein kinase to the cell surface ruffling membrane and the nucleus
62. Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts
63. Interaction of MAP kinase with MAP kinase kinase: Its possible role in the control of nucleocytoplasmatic transport of MAP kinase
64. Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation
65. Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins
66. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation
67. Nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and G2/M progression
68. Two co-existing mechanisms for nuclear import of MAP kinase: Passive diffusion of a monomer and active transport of a dimer
69. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry
70. Nuclear translocation of mitogen-activated protein kinase p42MAPK during ongoing cell cycle
71. Cell cycle-dependent activation of Ras
72. Cellular Ras activity is required for passage through multiple points of the G0-G1 phase in BALB-c3T3 cells
73. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH3T3 cells
74. Regulation of the cell cycle machinery by oncogenic ras
75. Activation of the MKK/ERK pathway during somatic cell mitosis: Direct interactions of active ERK with kinetochores and regulation of the mitotic 3T3/2 phosphoantigen
76. Evidence for MAP kinase activation during mitotic division
77. Active MAP kinase in mitosis: Localization at kinetochores and association with the motor protein CENP-E
78. Extracellular signal-regulated kinase activates topoisomerase IIa through a mechanism independent of phosphorylation
79. Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion
80. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
81. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
82. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
83. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells
84. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors
85. In vitro and in vivo effects of a farnesyltransferase inhibitor on NF-1-deficient hematopoietic cells
86. Involvement of caspase family proteases in FPT inhibitor III-induced apoptosis in human ovarian cancer cells
87. The farnesyltransferase inhibitor, FPT inhibitor III upregulates Bax and Bcl-xs expression and induces apoptosis in human ovarian cancer cells
88. U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways